, Volume 77, Issue 2, pp 105–108 | Cite as

Prevalence of abnormal involuntary movements (“spontaneous dyskinesias”) in the normal elderly

  • John M. Kane
  • Paul Weinhold
  • Bruce Kinon
  • James Wegner
  • Marcia Leader
Original Investigations


Advancing age has been associated with increased prevalence of abnormal involuntary movements in neuroleptic-treated patients. In order to investigate the possibility that the aging process itself might produce involuntary movements clinically indistinguishable from tardive dyskinesia, a group of healthy elderly volunteers were systematically examined. A 4% prevalence rate of mild involuntary movements was found, suggesting that the aging process itself is not likely to produce dyskinesias without other contributing factors coming into play.

Key words

Aging Dyskinesia Neuroleptic 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Altrocchi PH (1972) Spontaneous oral facial dyskinesia. Arch Neurol 26:506–512Google Scholar
  2. Brandon S, McClelland HA, Protheroe C (1971) A study of facial dyskinesia in a mental hospital population. Br J Psych 118:171–184Google Scholar
  3. Carlsson A (1976) Some aspects of dopamine in the basal ganglia. In: Yar MD (ed) The basal ganglia. Raven Press, New YorkGoogle Scholar
  4. Crane GE (1968) Dyskinesia and neuroleptics. Arch Gen Psychiatry 19:700–803Google Scholar
  5. Crane GW (1973) Persistent dyskinesia. Br J Psych 122:395–405Google Scholar
  6. Crane GE, Smeets RA (1974) Tardive dyskinesia and drug therapy in geriatric patients. Arch Gen Psychiatry 30:341–343Google Scholar
  7. Davis JM (1975) Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psych 132:1237–1245Google Scholar
  8. Degkwitz R, Binsack KF, Herkert H, et al. (1967) Zum Problem der persistierenden Hyperkinesen nach langfristiger Anwendung von Neuroleptika. Nervenarzt 38:170–174Google Scholar
  9. Delwaide PJ, Desseilles M (1977) Spontaneous buccolinguo facial dyskinesia in the elderly. Acta Neurol Scand 56:256–262Google Scholar
  10. Demars JPC (1966) Neuromuscular effects of long-term phenothiazine medication, electroconvulsive therapy and leukotomy. J Nerv Ment Dis 143:73–79Google Scholar
  11. Eckmann F (1968) Zur Problematik von Dauerschaden nach Neuroleptischer Langzeitbehandlung. Ther Ggw 107:316–323Google Scholar
  12. Freund C (1980) Cholinergic receptor loss in brains of aging mice. Life Sci 26:371–375Google Scholar
  13. Greenblatt DL, Dominick JR, Stotsky DA (1968) Phenothiazine induced dyskinesia in nursing home patients. J Am Geriat Soc 16:27–34Google Scholar
  14. Heinrich K, Wegner I, Bender HJ (1968) Spate extrapyramidale Hyperkinesen bei neuroleptischer Langzeit-Therapie. Pharmakopsychiatr Neuropsychopharmakol 1:169–195Google Scholar
  15. Hippius H, Lange J (1970) Zur Problematik der späten extrapyramidalen Hyperkinesen nach langfristiger neuroleptischer Therapie Arzneim Forsch 20:888–890Google Scholar
  16. Jones H, Hunter R (1969) Abnormal movements in patients with chronic psychiatric illness. In: Crane GE, Gardner R Jr (eds) Psychotropic drugs and dysfunction of the basal ganglia. Public Health Service Publication no. 1938, Washington DC, pp 53–62Google Scholar
  17. Kane JM, Smith JM (1982) Tardive dyskinesia: Prevalence and risk factors 1959–1979. Arch Gen Psychiatry, 39:473–481Google Scholar
  18. Klein DF, Davis JM (1969) Diagnosis and drug treatment of psychiatric disorders: Williams & Wilkins Co., BaltimoreGoogle Scholar
  19. Kraepelin (1919) Dementia praecox and paraphrenia, translated into English by Barclay RM. Roberts 1971. Robert E. Krieger Publishing Co., New YorkGoogle Scholar
  20. McGeer PL, McGeer EG, Suzuki JS (1977) Aging in extrapyramidal function. Arch Neurol 34:33–35Google Scholar
  21. Makman MH, Ahn HS, Thal LJ (1979) Aging and monoamine receptors in brain. Fed Proc 38:1922–1926Google Scholar
  22. Marsden CD (1976) Blephorospasm oromandibular dystonia syndrome Brueghel's syndrome. J Neurol Neurosurg Psychiatry 39:1204–1209Google Scholar
  23. Mettler FA, Crandell A (1959) Neurologic disorders in psychiatric institutions. J Nerv Ment Dis 128:148–159Google Scholar
  24. Pradhan SN (1980) Central neurotransmitters and aging: Mini-review. Life Sci 26:1643–1656Google Scholar
  25. Robinson DS, Davis JM, Neese A et al (1971) Relations of sex and aging to monoamine oxidase activity of human brain plasma and platelets. Arch Gen Psychiatry 24:536–639Google Scholar
  26. Siede H, Muller HF (1967) Choreioform movements as side effects of phenothiazine medication in geriatric patients. J Am Geriat Soc 15:517–522Google Scholar
  27. Simpson GM, Lee HJ, Zoubak B, Gardos GL (1979) A rating scale for tardive dyskinesia Psychopharmacology 64:171–179Google Scholar
  28. Smith JM, Baldessarini RJ (1980) Changes in prevalence, severity and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 37:1368–1373Google Scholar
  29. Smith RC, Leelavathide DE (1980) Behavioral and biochemical effects of chronic neuroleptic drugs: Interaction with age. In: Fann WE, Smith RC, Davis JM, Domino EF (eds) Tardive dyskinesia: Research and treatment. Spectrum Publications, Jamaica NY, pp 65–88Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • John M. Kane
    • 1
  • Paul Weinhold
    • 1
  • Bruce Kinon
    • 1
  • James Wegner
    • 1
  • Marcia Leader
    • 1
  1. 1.Department of PsychiatryLong Island Jewish-Hillside Medical CenterGlen OaksUSA

Personalised recommendations